NCT02381366View on ClinicalTrials.gov

Safety and Efficacy of PNEUMOSTEM® in Premature Infants at High Risk for Bronchopulmonary Dysplasia (BPD) - a US Study

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 31, 2015

Primary Completion Date

September 30, 2016

Study Completion Date

May 31, 2018

Conditions

Bronchopulmonary Dysplasia

Interventions

BIOLOGICAL

Human Umbilical Cord Blood Derived-Mesenchymal Stem Cells

"Human Umbilical Cord Blood Derived-Mesenchymal Stem Cells:~Dose A: 10 million cells per kg / Dose B: 20 million cells per kg"

Trial Locations (1)

60612

Rush University Medical Center, Chicago

All Listed Sponsors

collaborator

Medipost Co Ltd.

INDUSTRY

lead

Medipost America Inc.

INDUSTRY

NCT02381366 - Safety and Efficacy of PNEUMOSTEM® in Premature Infants at High Risk for Bronchopulmonary Dysplasia (BPD) - a US Study | Biotech Hunter | Biotech Hunter